431 related articles for article (PubMed ID: 30137025)
21. Identification and validation of a ferroptosis-related lncRNA signature to robustly predict the prognosis, immune microenvironment, and immunotherapy efficiency in patients with clear cell renal cell carcinoma.
Ju L; Shi Y; Liu G
PeerJ; 2022; 10():e14506. PubMed ID: 36570012
[TBL] [Abstract][Full Text] [Related]
22. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
[TBL] [Abstract][Full Text] [Related]
23. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
[TBL] [Abstract][Full Text] [Related]
24. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
Panda A; de Cubas AA; Stein M; Riedlinger G; Kra J; Mayer T; Smith CC; Vincent BG; Serody JS; Beckermann KE; Ganesan S; Bhanot G; Rathmell WK
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135306
[TBL] [Abstract][Full Text] [Related]
25. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
[TBL] [Abstract][Full Text] [Related]
26. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
[TBL] [Abstract][Full Text] [Related]
27. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma.
Wei B; Yu M; Yao J; Jiang M; An J; Yang J; Lin J; Zhao Y; Zhu Y
Front Immunol; 2021; 12():657951. PubMed ID: 34531849
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatics analysis of immune-related prognostic genes and immunotherapy in renal clear cell carcinoma.
Pan Z; Chang S; Chen S; Zhao D; Zou Z; Dai L; Hou Y; Zhang Q; Yang Y; Chen Z; Zhang W; Zhao Y
PLoS One; 2022; 17(11):e0272542. PubMed ID: 36417422
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
Ghatalia P; Gordetsky J; Kuo F; Dulaimi E; Cai KQ; Devarajan K; Bae S; Naik G; Chan TA; Uzzo R; Hakimi AA; Sonpavde G; Plimack E
J Immunother Cancer; 2019 May; 7(1):139. PubMed ID: 31138299
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches.
Müller MD; Holst PJ; Nielsen KN
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163254
[TBL] [Abstract][Full Text] [Related]
31. Identification of Ligand-Receptor Pairs Associated With Tumour Characteristics in Clear Cell Renal Cell Carcinoma.
Liu F; Wang P; Sun W; Jiang Y; Gong Q
Front Immunol; 2022; 13():874056. PubMed ID: 35734169
[TBL] [Abstract][Full Text] [Related]
32. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
[TBL] [Abstract][Full Text] [Related]
33. Human endogenous retroviruses and cancer prevention: evidence and prospects.
Cegolon L; Salata C; Weiderpass E; Vineis P; Palù G; Mastrangelo G
BMC Cancer; 2013 Jan; 13():4. PubMed ID: 23282240
[TBL] [Abstract][Full Text] [Related]
34. Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
Steiner MC; Marston JL; Iñiguez LP; Bendall ML; Chiappinelli KB; Nixon DF; Crandall KA
Cancer Res; 2021 Jul; 81(13):3449-3460. PubMed ID: 33941616
[TBL] [Abstract][Full Text] [Related]
35. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response.
Hajiran A; Chakiryan N; Aydin AM; Zemp L; Nguyen J; Laborde JM; Chahoud J; Spiess PE; Zaman S; Falasiri S; Fournier M; Teer JK; Dhillon J; McCarthy S; Moran-Segura C; Katende EN; Sexton WJ; Koomen JM; Mulé J; Kim Y; Manley B
Clin Exp Immunol; 2021 Apr; 204(1):96-106. PubMed ID: 33346915
[TBL] [Abstract][Full Text] [Related]
36. Leveraging diverse cell-death related signature predicts the prognosis and immunotherapy response in renal clear cell carcinoma.
Wu Z; Jin M; Xin P; Zhang H
Front Immunol; 2023; 14():1293729. PubMed ID: 38146369
[TBL] [Abstract][Full Text] [Related]
37. DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma.
Bao Y; Jiang A; Dong K; Gan X; Gong W; Wu Z; Liu B; Bao Y; Wang J; Wang L
Int J Biol Sci; 2021; 17(12):3158-3172. PubMed ID: 34421357
[TBL] [Abstract][Full Text] [Related]
38. NKG2A
Qiu Y; Liu L; Jiang W; Xu Z; Wang J; Dai S; Guo J; Xu J
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38262706
[TBL] [Abstract][Full Text] [Related]
39. HERVK-mediated regulation of neighboring genes: implications for breast cancer prognosis.
Liang B; Yan T; Wei H; Zhang D; Li L; Liu Z; Li W; Zhang Y; Jiang N; Meng Q; Jiang G; Hu Y; Leng J
Retrovirology; 2024 Feb; 21(1):4. PubMed ID: 38388382
[TBL] [Abstract][Full Text] [Related]
40. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
